Omeros Shares Plunge After CHMP Rejects Narsoplimab for TA-TMA
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
/ 352 items
#XY Event-Driven Stocks↓
After Re-examination, CHMP Recommends Approval of DAYBU for Rett Syndrome in the EU
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
Tempus AI Shares Rise on New Angiosarcoma Research Collaboration
Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.
ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins
Despite the setback, Florida Medicaid coverage begins July 1, the company cut 2026 expenses to $248M, and it remains on track for cash-flow breakeven in 2027.
Merck KGaA Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition
Acquisition of a medical tools maker will be the German group’s biggest in over a decade.
Passage Bio to Merge with Remix Therapeutics in All-Stock Deal, Raises $100 Million
The combined company will operate as Remix Therapeutics and raised $100M to advance its RNA-targeted pipeline into 2028.